NCT07467213 Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
| NCT ID | NCT07467213 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Samsung Medical Center |
| Condition | Acute Myocardial Infarction (AMI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-06-23 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 5,000 participants in total. It began in 2026-06-23 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).
Eligibility Criteria
Inclusion Criteria: * Patients aged 19 years or older. * Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \[STEMI\] or non-ST-segment elevation myocardial infarction \[NSTEMI\]). * Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB). * Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent. Exclusion Criteria: * History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \[P-CAB\] or proton pump inhibitor \[PPI\]). * Presence of active gastrointestinal bleeding. * Pregnant or breastfeeding women. * Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment). * Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.
Frequently Asked Questions
Who can join the NCT07467213 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Acute Myocardial Infarction (AMI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07467213 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 5,000 participants.
Is NCT07467213 currently recruiting?
Yes, NCT07467213 is actively recruiting participants. Visit ClinicalTrials.gov or contact Samsung Medical Center to inquire about joining.
Where is the NCT07467213 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07467213 clinical trial?
NCT07467213 is sponsored by Samsung Medical Center. The trial plans to enroll 5,000 participants.